Nexpovio (Selinexor)

Selinexor, the active ingredient in Nexpovio, is a selective inhibitor of nuclear export (SINE) presented as an oral tablet for oral use. It treats relapsed/refractory multiple myeloma and relapsed/refractory diffuse large B‑cell lymphoma in adult patients who have exhausted standard therapies.

GNH USA supplies Nexpovio as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Nexpovio (selinexor) is indicated for hematologic malignancies that are refractory to standard therapies.

- Relapsed/refractory multiple myeloma: improves disease control and extends progression‑free survival in patients who have received at least two prior lines of therapy. - Relapsed/refractory diffuse large B‑cell lymphoma: provides an additional therapeutic option for patients whose disease has progressed after standard chemoimmunotherapy.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Nausea and vomiting: gastrointestinal upset often managed with antiemetics. - Anorexia: reduced appetite leading to weight loss. - Diarrhea: loose stools that may require hydration. - Thrombocytopenia: lowered platelet count increasing bleeding risk.

Serious or Rare Side Effects: - Severe neutropenia: markedly reduced neutrophils predisposing to infection. - Hyponatremia: low blood sodium that can cause neurological symptoms. - Severe thrombocytopenia: heightened risk of serious bleeding events. - Infections: opportunistic or serious bacterial, viral, or fungal infections.

Before initiating therapy, clinicians should evaluate baseline laboratory values and monitor patients regularly. - Monitor blood counts: perform complete blood count with differential at baseline and periodically. - Assess electrolytes: check serum sodium and correct abnormalities promptly. - Evaluate hepatic function: adjust use in patients with moderate hepatic impairment. - Provide antiemetic prophylaxis: consider routine anti‑nausea medication to improve tolerability. - Store at below 25°C: keep tablets in the original container, protect from moisture and direct sunlight.

Selinexor may interact with other medicines that affect its metabolism or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce selinexor exposure and efficacy. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase selinexor levels and risk of adverse events.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): monitor INR and adjust dose as needed. - CYP3A4 substrate drugs (e.g., midazolam): may require dose adjustment. - P‑gp inhibitors or inducers: could alter selinexor absorption; observe therapeutic response.